PAVmed

PAVmed is a diversified medtech company founded in 2014 by surgeons and an industry executive with an imperative to innovate across sectors. Its core strategy is a shared-services business model that provides centralized expertise to its portfolio of subsidiaries, aiming for efficient scale and de-risked commercialization. Current commercial momentum is driven by its subsidiaries Lucid Diagnostics, commercializing the EsoGuard® test for esophageal precancer, and Veris Health, focused on remote patient monitoring for oncology.

PAVmed's core platform is its shared-services business model, which provides centralized corporate, regulatory, clinical, and operational expertise to a diversified portfolio of medical technology subsidiaries across diagnostics and digital health.

Lucid competes against traditional endoscopy and emerging non-endoscopic tests like the Cytosponge, leveraging its FDA-cleared DNA assay. Veris competes in a crowded digital health RPM market but seeks differentiation through its oncology-specific focus, integrated devices, and membership in consortia like CancerX.